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Background: Medicines can constitute up to 70% of total health care budgets
in developing countries as well as considerable expenditure in hospitals. Inventory
management techniques can assist with managing resources efficiently. In Kenyatta
National Hospital (KNH), a leading hospital in Kenya, over 30% of expenditure is currently
allocated to medicines, and this needs to be optimally managed.
Objective: To investigate drug consumption patterns, their costs and morbidity
patterns at KNH in recent years.
Methodology: Cross-sectional retrospective record review. Inventory control
techniques, ABC (Always, Better, and Control), VEN (Vital, Essential, and Non-
essential) and ABC-VEN matrix analyses were used to study drug expenditure patterns.
Morbidity data was extracted from the Medical Records.
Results: Out of an average of 811 medicine types procured annually (ATC 5), 80%
were formulary drugs and 20% were non-formulary. Class A medicines constituted
13.2–14.2% of different medicines procured each year but accounted for an average
of 80% of total annual drug expenditure. Class B medicines constituted 15.9–17% of
all the drugs procured yearly but accounted for 15% of the annual expenditure, whilst
Class C medicines constituted 70% of total medicines procured but only 5% of the total
expenditure. Vital and Essential medicines consumed the highest percentage of drug
expenditure. ABC-VEN categorization showed that an average of 31% of medicine
types consumed an average of 85% of total drug expenditure. Therapeutic category
and Morbidity patterns analysis showed a mismatch between drug expenditure and
morbidity patterns in over 85% of the categories.
Conclusion: Class A medicines are few but consume the largest proportion of hospital
drug expenditure. Vital and essential items account for the highest drug expenditure,
and need to be carefully managed. ABC-VEN categorization identified medicines
where major savings could potentially be made helped by Therapeutic category and
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Morbidity pattern analysis. There was a high percentage of non-formulary items, which
needs to be addressed. Inventory control techniques should be applied routinely to
optimize medicine use within available budgets especially in low and middle income
countries.
Keywords: ABC analysis, VEN analysis, medicines, hospitals, expenditure, Kenya
INTRODUCTION
Medicines have been used across countries to alleviate patients’
suffering and improve their lives with an agreed list of essential
medicines to reduce morbidity and mortality (Hogerzeil et al.,
2013; Wirtz et al., 2017). Medicines are now typically seen as
one of the most cost-effective interventions to improve health
especially as more standard medicines lose their patent and
become available as low cost generics or biosimilars (Simoens,
2012; Godman et al., 2014b, 2017a; Moorkens et al., 2017).
However, the inappropriate use of medicines can appreciably
increase costs through adverse drug reactions (ADRs), drug–drug
interactions, and wasted resources, compromising the quality of
care and increasing mortality (WHO, 2002; Davies et al., 2009;
Wu et al., 2010; Godman et al., 2013; Dechanont et al., 2014;
Mouton et al., 2015; Kiguba et al., 2017).
Overall, medicines constitute an appreciable component of
total health care costs (Clemente et al., 2008; Lu et al., 2011),
comprising up to 20–40% of health care budgets in many
developing countries (Cameron et al., 2009; Lu et al., 2011). This
may increase up to 70% in low and low-middle income countries
(LMICs) (mean of 27.6–30.4%), where there are also appreciable
co-payments (Cameron et al., 2009; Lu et al., 2011; Ofori-Asenso
and Agyeman, 2016; Nguyen et al., 2015). Co-payments can
account for up to 76.9% of total pharmaceutical expenditure,
which can potentially be catastrophic for the family in terms
of purchasing essentials such as food alongside medicines if
family members become seriously ill (Cameron et al., 2009;
Nguyen et al., 2015). For instance in Kenya, even the cost of
one radiotherapy session at US$5 – 10 for patients with cancer
in the major public hospital can be prohibitively expensive for
disadvantaged Kenyans who have to pay this as they typically
live on US$1 per day or less, and the estimated costs of treating
patients with cancer of up to US$5000/patient is just unaffordable
for the majority of patients and their families (Mbui et al., 2017;
Osman, 2017; Atieno et al., 2018). Schemes have now been
launched by pharmaceutical companies in Kenya to increase
access to essential medicines for patients with cardiovascular
diseases given current concerns with affordability and outcomes
(Sandoz, 2015; Mbui et al., 2017).
Within hospitals, the appropriate use of medicines, and their
availability, is vital to improve the care of patients within
available resources aiding early discharge. The irrational use of
use of medicines in hospitals can lead to a number of problems
including reduced access to essential medicines, reduced patient
attendance rates due to stock outs and loss of patient confidence
in the healthcare system, as well as increasing ADRs and length
of stay (WHO, 2002; Davies et al., 2009; Holloway and van
Dijk, 2011; Kiguba et al., 2017). Health institutions should aim
at stocking an agreed range of medicines along with initiatives
to improve their use and the supply chain to address concerns
(Meyer et al., 2017). Essential medicines are defined by the World
Health Organization (WHO) as “those that satisfy the priority
health care needs of the population”, and are selected “with due
regard to public health relevance, evidence on efficacy and safety,
and comparative cost-effectiveness” (WHO, 2017b). Selecting such
medicines across countries typically begins with defining a list
of common diseases for each level of healthcare; subsequently
selecting first and second line treatment choices for hospital
formularies and Standard Treatment Guidelines (STG). This has
been exemplified for instance in Scotland with their Regional
formularies and in Sweden with their regional formularies such
as the ‘Wise List’ in Stockholm County Council (Gustafsson et al.,
2011; Bjorkhem-Bergman et al., 2013).
Improved management of medicines in hospitals should lead
to improved medicines availability thereby improving patient
outcomes and reducing morbidity and mortality (Pillans et al.,
1992). In view of this, pharmaceutical stores need to be planned,
designed, organized and maintained in a manner that results in
efficient clinical and administrative services (Khurana et al., 2013;
Meyer et al., 2017).
Methods used to identify irrational medicine use include
instigating drug utilization studies using the Anatomical
Therapeutic Chemical/Defined Daily Dose (ATC/DDD)
methodologies, Drug Use Evaluation (DUE) and qualitative
methods to assess the extent of current utilization patterns
and any concerns (WHO, 2003; Godman et al., 2016). This
includes aggregate data methods such as ABC analysis,
Therapeutic Category (TC) analysis and VEN analysis, which
is an inventory categorization method whereby medicines are
classified according to their perceived public health impact
into vital, essential and non-essential. These methods are used
by Drug and Therapeutic Committees (DTCs), particularly
in LMIC countries, to better manage their formulary lists
and identify gaps in drug use (Laing et al., 2001; Kumar and
Chakravarty, 2015). ABC analysis groups medicines based on
their cumulative cost percentage. Class A medicines constitute
10–20% of the medicines within hospitals but typically account
for 70–80% of the total drug budget; Class B medicines comprise
the next 10–20% of available medicines but consume 15–20%
of the drug budget; with Class C medicines constituting the
remaining 60–80% of medicines in the facility but accounting
for only 5–10% of the annual drug budget (Quick et al., 1997;
Holloway and Green, 2003; Management Sciences for Health
and World Health Organization, 2007; WHO, 2012). VEN
analysis (Vital – V, Essential – E, and Non-Essential – N)
subsequently, as mentioned, classifies medicines based on
their perceived public health impact. Vital medicines (V) are
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potentially life-saving, have significant side-effects or have major
public health importance. Essential medicines (E) are effective
against less severe but significant forms of disease, but are not
absolutely vital to providing basic healthcare. Non-essential
medicines (N) are used for minor or self-limiting illnesses, are of
questionable efficacy and typically have a high cost for marginal
therapeutic gain (Management Sciences for Health and World
Health Organization, 2007; WHO, 2012). Such analyses have
worked well in LMICs including areas such as cancer, which
are a growing priority with increasing prevalence rates as well
as increasing costs of medicines (Godman et al., 2017b; Atieno
et al., 2018; Jakupi et al., 2018).
No institution in LMIC countries typically has adequate funds
to fully procure all suggested medicines on the formulary list,
especially with medicines already typically accounting for a third
of total hospital expenditure, which is generally the case in
tertiary hospitals in these countries (Kumar and Chakravarty,
2015). This requires prudent selection of medicines that is
evidence based, coupled with setting priorities that will enable
institutions to improve their overall efficiency of medicine use
given ongoing concerns with medicine availability and their
costs (WHO, 1999; Kumar and Chakravarty, 2015). ABC-VEN
analyses may be employed in hospitals to enhance future
selection and stock management (Quick et al., 1997; Thawani
et al., 2004; Ramanathan, 2006; Gupta et al., 2007; Devnani et al.,
2010; Anand et al., 2013; Jakupi et al., 2018).
However, accurate knowledge of medicine use and priorities
among hospitals in Kenya is still inadequate. Consequently,
the objectives of this study were to determine and compare
medicine classes that accounted for the greatest proportion
of the drug budget in a leading tertiary hospital in Kenya,
Kenyatta National Hospital (KNH); secondly, determine and
compare medicine use according to their potential health affects
(VEN), and lastly to rationalize the therapeutic categories
of medicine use. The findings will be used to guide future
interventions in this hospital and wider, with the goal of
improving the rational use of medicines, with KNH setting
the trend for other hospitals in Kenya through its training
and comprehensive services. As such, seek to maximize patient
outcomes within available resources. We believe this is the
first time that such an extensive analysis has been undertaken
in Kenya, providing guidance to other hospital facilities in
Kenya and wider among secondary and tertiary hospitals across
Africa.
METHODOLOGY
Study Design
The ABC analysis was conducted as a retrospective cross sectional
record review. For each year of the study (2013–2015), annual
consumption data along with the related expenditure incurred
on each item was retrieved from the pharmaceutical stores of
KNH, which are located on the ground floor of the hospital. Data
was subsequently transferred into the ABC Analyzer 5, 80/20
Analytics (a software under development and license number
granted 8579574233285627).
The ABC analyzer grouped the listed medicines into the three
categories – A, B, and C, based on the cumulative cost percentage
of 80, 15, and 5%, respectively. The VEN analysis was a
descriptive retrospective study. The VEN status of each medicine
was obtained from the KNH formulary and the Kenya Essential
Medicines List (KEML), both of which were developed by a
multidisciplinary team of key specialists including physicians,
surgeons, pediatricians, and pharmacists (Quick et al., 1997; The
Ministry of Medical Services and Ministry of Public Health &
Sanitation Kenya, 2010; Ministry of Health Republic of Kenya,
2016).
After performing the ABC analysis, the medicines were
assigned to a therapeutic category to develop a morbidity pattern
for drug use. This was based on the KNH formulary, the World
Health Organization (WHO) model list of Essential medicines,
the Anatomical Therapeutic Chemical (ATC) codes (WHO,
2013) and the International classification of diseases (ICD-10)
developed by the WHO. In addition, the annual morbidity
data for the years 2013–2015 was extracted from KNH’s Health
information database and entered into an MS Excel spreadsheet
for analysis.
Study Site
The study was conducted at KNH which is a 2000 bed
national teaching and referral hospital in Kenya with an annual
average of 70,000 inpatients and 500,000 outpatients. KNH
is the largest public referral hospital in the region, offering
quality specialized healthcare to patients from across Kenya,
Great lakes region, Southern and Central Africa (Kenyatta
National Hospital, 2014). KNH also offers most of the medical
specialty and related services including specialized surgeries
such as open heart surgery, neurosurgery, critical care services,
oncology, burns management and renal services (including
kidney transplantation). KNH also launched its formulary in
September 2013 with the support of Management Sciences for
Health (MSH) (Otieno, 2013), providing guidance to other
hospitals in Kenya.
Kenyatta National Hospital has a Supply Chain department
which is responsible for the purchase, storage of medicines,
and other medical supplies, across the hospital. There are also
a number of donor funded programs that are also handled
by the Supply Chain department including HIV/AIDS and
Malaria programs. Most of the records in the Supply Chain
department are manual but as from 2014 a Health Management
Information System (HMIS) was launched; however, it is still
not fully operational. The procurement of medicines follows the
government system of tendering and the lowest bidder wins the
tender.
Sources of Data
The data sources included S3 cards (Stores Ledger and Stock
Control card), S5 cards (Bin cards, records stock movement), S13
cards (Counter receipt voucher cards), S11 (Issue voucher), the
security receiving book as well as HMIS and any other relevant
records that could provide pertinent consumption data, prices
and annual morbidity.
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Inclusion and Exclusion Criteria
The study included the drug procurement records for the years
2013–2015. Records for medicines procured directly under the
Pharmacy budget were included. The study also included records
of any medicines borrowed, donated or returned to the store.
S11 were used for medicines borrowed and S13 for medicines
donated.
The study excluded medical gasses, mainly oxygen and
nitrogen, dialysis solutions and some dressing for burns that
were not procured under the pharmacy budget. The study also
excluded records of medicines kept at the Private Wing Store,
which are procured independently of the Main Hospital, as
we just wanted to concentrate on the public health system
where the majority of patients are treated. For the TC and
morbidity data, the study excluded ICD-10 classes whose
annual morbidity data were missing. ICD-10 classes which did
not have identifiable medicines were also excluded from the
study.
Sample Size and Sampling Method
A universal sampling technique was used whereby every record
with relevant information to the study was included. A sample
size determination was not conducted for the ABC, VEN, and TC
analysis since this was an annual expenditure study, and every
record was included in the analysis to obtain the most accurate
expenditure and consumption data (medicine type by ATC class
as opposed to utilization broken down by defined daily doses)
as possible. This is in line with previous publications (Migbaru
et al., 2009; Anand et al., 2013; Kumar and Chakravarty, 2015;
Kastanioti et al., 2016; Mousnad et al., 2016).
Data Collection Procedures
A data collection tool was adapted from WHO studies for the
ABC and TC analysis (Holloway and Green, 2003; Rankin, 2012).
The relevant information included the drug code, drug name,
pharmaceutical formulation, unit of issue, quantity and unit
price. Data for the VEN categorization were obtained from the
KNH formulary and the KEML (The Ministry of Medical Services
and Ministry of Public Health & Sanitation Kenya, 2010; Otieno,
2013; Ministry of Health Republic of Kenya, 2016). The morbidity
data was extracted and entered onto a predesigned data collection
form as per the WHO- ICD-10 system for the years 2013 to 2015
by a research assistant trained on the use of the data extraction
forms.
Study Variables and Definitions
For the ABC analysis, the outcome variables of interest were the
number of medicine types (ATC 5) belonging to the A, B, and C
classes and their percentage annual expenditure. The ABC-VEN
matrix also categorizes medicines into three categories of interest
(Category I, II, and III). Category I comprised of medicines in
the AV, AE, AN, BV, and CV categories. Category II comprised
of medicines in the BE, BN, and CE categories, and Category
III in the remaining CN category, i.e., the first letter is from
the ABC analysis and the second letter from the VEN analysis.
For the TC and Morbidity analysis, the main outcome variable
was the proportion of expenditure that matched the morbidity
patterns. Annual morbidity data was entered into the health
information system (HIS) by the Medical Record staff at the
Health Information Department using the ICD-10 system.
The data entered on a daily basis was aggregated annually to give
the number of cases of each disease encountered in the hospital
for the whole year.
Quality Assurance and Data
Management
Double manual data entry was performed as part of quality
assurance. Firstly onto the predesigned data collection tool and
subsequently onto the MS Excel designed form. This approach
was undertaken to improve the accuracy of the data for analysis.
Verification of the data was undertaken to ensure the collected
and recorded data was accurate by randomly sampling the
entries and cross checking them with the source documents.
The data collected were cleaned by cross checking, which
included removing errors such as double entries and misplaced
information. A daily backup was undertaken using a flash disk
which was password protected. All the backups were stored
under lock and key with only the researcher having access to
the keys. The researcher verified all the information entered
in the Microsoft Excel worksheet on a daily basis to ensure
correct entries. A pilot study was performed beforehand to ensure
the data collection forms fully captured all the information
required.
Data Analysis
As mentioned, the ABC analysis was conducted using the ABC
analyzer 5, 80/20 Analytics (a software under development
and license number granted 8579574233285627). The data was
subsequently transcribed onto an MS Excel spreadsheet for
quantitative analysis. The statistical analysis was carried out
using MS Excel statistical functions. The annual expenditure
of individual items was calculated by multiplying the annual
drug consumption by the unit price (Consumption × Cost)
and arranged in descending order. The percentage of annual
drug expenditure and cumulative drug expenditure percentages
were subsequently calculated. The VEN classification of the
medicines was based on the KNH formulary and the KEML.
The medicines were classified using a pre-designed form
and the total percentage of expenditure for each category
calculated.
For the ABC-VEN matrix analysis, a comparison of the ABC
analysis with the VEN classification was subsequently undertaken
to populate the ABC-VEN matrix, which comprised the three
categories, namely Category I, II, and III.
Expenditure for each category was calculated from the ABC
analysis, with the data subsequently transferred onto an Excel
spreadsheet for quantitative analysis. Each ICD-10 class was
matched with the expenditure on medicines for that class. The
cumulative cost of the medicines in each category was calculated
and the percentage of total expenditure for each year also
calculated. Utilization was based on each drug name (ATC code)
and the units of issue. We used a conversion rate of USD 1 = KES
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101.3 (Central bank of Kenya1) to convert drug expenditure data
from Kenya shillings to United States Dollars in line with recent
publications (Atieno et al., 2018).
Ethics Statement
Ethical approval was sought from the KNH-UoN Ethics and
Research Committee to conduct the ABC, VEN, TC analysis
and approval was received in February 2016, approval number
P668/10/2015. Since the Pharmaceutical store is under Supplies
department, the records were assessed after getting authority.
RESULTS
Annual Consumption and Expenditure on
Drugs at KNH
A total of 812 different medicines (ATC 5) were procured in
2013 and 811 in 2014 and 2015 of which 652 (80%) were in the
formulary and 159 (20%) were non-formulary. The total number
of different medicines procured and their expenditure for the
period 2013–2015 is shown in Table 1.
ABC Analysis
Class A drugs represented 107 (13.2%), 110 (13.6%) and 115
(14.2%) of the total medicines analyzed for the years 2013, 2014,
and 2015, respectively. Class A medicines consumed the largest
proportion of the total budget at 79.9% for 2013 and 2014
and 79.8% for 2015. Class C medicines represented the highest
number of different medicines at 576 (70.9%), 566(69.8%), and
558 (68.8%) for 2013, 2014, and 2015, respectively. These class C
medicines consumed only an average of 5% of the total budget.
The trend for 3 years was similar as shown in Table 2.
1www.centralbank.go.ke/forex/
From the ABC analysis, the top 10 different medicines for each
year and their units of issue from 2013 to 2015 were identified
(Table 3).
The results show that there is a decrease in expenditure for
sodium chloride infusion, heparin injections and recombinant
granulocyte colony stimulating factor (G-CSF) over the 3 years,
whilst there was an increase in expenditure on meropenem,
acyclovir and isoflurane from 2013 to 2015. The Injection
three chamber bag was overtaken in expenditure by triple
chamber parenteral nutrition in 2015. These bags contain three
components namely: glucose 19%, amino acid combinations and
intra lipids (20%), which are reconstituted for total parenteral
nutrition.
VEN Analysis
The VEN analysis showed that Vital items (V) accounted for an
average of 22.8% (185) of the different medicine types procured
over the 3 years, Essential items (E) for 53.3% (432) and Non-
essential items accounted for 23.9% (194) the different medicine
types procured (Table 4). The findings also revealed that there
were a number of non-formulary (NF) items procured and
consumed in the hospital during the 3 years, and these accounted
for an average of 17.4% (141) of all medicine types procured.
Human normal immunoglobulin 5% was the most expensive
non-formulary medicine procured during the last 2 years of the
study period. It accounted for 0.9% of total expenditure in 2014,
increasing to 3% of total expenditure in 2015.
The percentage annual expenditure on medicines is based on
the annual drug expenditure shown in Table 1.
ABC-VEN Matrix Analysis
Results of the ABC-VEN matrix analysis for KNH from
2013–2015 are shown in Table 5. The percentage annual
expenditure on medicines is again based on the annual drug
expenditure shown in Table 1.
TABLE 1 | Annual expenditures on medicines at KNH drug store for 2013–2015.
Year Total number of
medicine types
procured
Drug expenditure
in Kshs
Total expenditure
in USD$
% of Total annual
hospital
expenditure
2013 812 400,625,444.17 3,954,841.5 33%
2014 811 406,391,886.87 4,011,765.9 33%
2015 811 452,064,244.35 4,462,628.3 34%
Total 1,259,081,575.39 12,429,235.7
TABLE 2 | ABC Analysis of the different medicine types at the KNH drug store for the period 2013–2015.
Analysis parameter N (%) of medicine types procured % Total annual hospital expenditure on
medicines
2013 2014 2015 2013 2014 2015
A 107 (13.2) 110 (13.6) 115 (14.2) 79.9 79.9 79.8
B 129 (15.9) 135 (16.6) 138 (17) 15.1 15 15.1
C 576 (70.9) 566 (69.8) 558 (68.8) 5 5.1 5.1
Total 812 811 811 100 100 100
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The results showed that the highest costing medicines, which
are also in the Vital and Essential category, consumed the highest
expenditure on medicines. On average, AV drugs accounted for
36 (4.5%) of the different medicine types consumed but 28.7% of
total expenditure on medicines, with AE drugs accounting for on
average 67 (8.2%) of the different medicines consumed but 46.8%
of the total expenditure on medicines (Table 5). The cheaper and
non-essential medicines (CN class) consumed on average only 1%
of the total expenditure on medicines.
ABC-VEN categorization revealed that 247 (30.4%), 249
(30.7%), and 259 (31.9%) medicines belonged to Category I for
2013, 2014, and 2015, respectively, and consumed approximately
85% of total annual expenditure on medicines (Table 6). Category
II had the majority of the items and consumed an average amount
of total drug expenditure, with Category III items consuming
only an average of 1% of the total medicine expenditure over the
3 years (Table 6).
Therapeutic Category and Morbidity
Pattern Analysis
The annual morbidity for KNH is shown in Table 7. The
morbidity data for 2013 were only partially available; consequently
this is not presented in Table 7. The annual morbidity data in
descending order for 2014 and 2015 shows almost a similar pattern
with ICD-10 class S00-T99 (Injuries, poisoning and certain other
consequences of external cause, Burns) having the highest number
of cases and ICD-10 class H00-H59 (Diseases of the eye and
Adnexa) having the least number of cases.
Average morbidity data patterns from 2013 to 2015, and
average annual consumption expenditure on medicines, was
computed from the ABC analysis data and tabulated as shown
in Table 8 and Figure 1.
When the percentage annual number of cases and annual drug
consumption expenditure was calculated, the results showed that
certain infectious and parasitic diseases (ICD-10 class A00-B99)
had the highest annual drug expenditure (26.3%), with medicines
for neoplasms the second highest expenditure (19%) (Table 8).
Diseases of the skin and subcutaneous tissue (ICD-10 class
L00-L99) had the lowest annual drug expenditure (0.3%). The
highest number of cases seen in KNH was, as mentioned, in
the ICD-10 class S00-T99 (Injuries, poisoning and certain other
consequences of externals causes, burns).
Two ICD-10 classes showed almost a similar annual number
of cases and annual drug expenditure, i.e., ICD-10 class F00-
F99 (Mental, behavioral disorders) and H00-H59 (Disease of
the eye and Adnexa) at 0.7 and 0.6%, respectively. Some ICD-
10 classes had a higher annual drug expenditure compared to
the annual number of cases, i.e., ICD-10 class I00-I99 (Diseases
of circulatory system) and S00-T99 (Injuries, poisoning and
certain other consequences of external causes, Burns) at 6 and
11.2% for the number of cases seen and 13.1 and 14.9% for
drug expenditure, respectively. Annual drug expenditure is again
based on the figures in Table 1.
Further analysis of the expenditure on medicines based on the
KNH Formulary showed an increase in expenditure in 2015 for
anesthetic and theater agents and Immunologicals, and a decrease
in expenditure on plasma substitutes (Table 9).
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TABLE 4 | VEN analysis of medicines at KNH drug store for the period 2013–2015.
Analysis parameter N (%) of total medicine types procured % Annual expenditure on medicines
2013 2014 2015 2013 2014 2015
V 177 (21.8) 201 (24.8%) 178 (21.9) 37.7 36.3 27.3
E 433 (53.3) 433 (53.4) 431 (53.1) 56.8 57.6 61
N 202 (24.9) 177 (21.8) 202 (24.9) 5.5 6.1 11.8
Total 812 (100) 811 (100) 811 (100) 100 100 100
TABLE 5 | ABC-VEN matrix analysis of medicines procured at KNH drug store for 2013–2015.
Analysis parameter N (%) of total medicine types procured % Annual expenditure on medicines
2013 2014 2015 2013 2014 2015
AV 37 (4.6) 38 (4.7) 34 (4.2) 32.6 31.5 22.1
AE 64 (7.9) 66 (8.0) 70 (8.6) 44.7 45.9 49.9
AN 6 (0.7) 6 (0.7) 11 (1.4) 2.6 2.5 7.9
BV 34 (4.2) 33 (4.1) 35 (4.3) 4.0 3.7 3.9
BE 81 (10) 81 (10) 75 (9.3) 9.2 9.1 8.3
BN 15 (1.8) 21 (2.6) 28 (3.5) 2.0 2.3 2.9
CV 106 (13.1) 106 (13.1) 109 (13.4) 1.1 1.1 1.3
CE 288 (35.5) 286 (35.3) 286 (35.3) 2.9 2.6 2.8
CN 181 (22.3) 174 (21.5) 163 (20.1) 0.9 1.3 1.0
Total 812 (100) 811 (100) 811 (100) 100 100 100
TABLE 6 | ABC-VEN Matrix categorization for medicines at the KNH drug store for 2013–2015.
Analysis parameter N (%) of total medicine types procured % Annual expenditure on medicines
2013 2014 2015 2013 2014 2015
Category I 247 (30.4) 249 (30.7) 259 (31.9) 85.0 84.7 85.0
Category II 384 (47.3) 388 (47.8) 389 (48.0) 14.1 14.0 14.0
Category III 181 (22.3) 174 (21.5) 163 (20.1) 0.9 1.3 1.0
Total 812 (100) 811 (100) 811 (100) 100 100 100
Medicines for patients with cancer and immunosupressive
medicines were the highest expenditure across all 3 years
accounting for 16–18% of total expenditure (Table 9), consistent
with the morbidity patterns (Table 8).
DISCUSSION
ABC-VEN
Class A medicines were the fewest yet they consumed the highest
percentage of total drug expenditure over the 3 years while
class B constituted on average 17% but consumed approximately
15% of the annual expenditure (Table 2). Classes A and B
medicines, which were an average of 245 medicine types for
the 3 years, consumed 95% of the total drug expenditure, with
the remaining Class C medicines, despite being the majority of
medicine types, consumed only 5% of total drug expenditure
(Table 2).
As a consequence of this, medicines belonging to Class A
require more stringent managerial control, including assessing
the appropriateness of prescribing within finite budgets, which is
similar to activities in Europe for new premium priced medicines
(Godman et al., 2014a, 2015, 2016; Kastanioti et al., 2016;
Mousnad et al., 2016; Jakupi et al., 2018), as well as accurate data
to drive forecasting of future demand, building on examples in
other countries (Wettermark et al., 2010; Eriksson et al., 2017).
Alongside this, close and frequent checks on budgets and stock
levels as well as judicious purchasing, issuing of and inspection
of medicines prescribed. It is with Class A medicines that the
hospital can make maximum savings with its budget if pertinent
with a reduction in the use of less cost-effective medicines in
this category (Holloway and Green, 2003; Kastanioti et al., 2016;
Mousnad et al., 2016). This may mean looking at issues of
disinvestment in some categories (Parkinson et al., 2015; Brett
et al., 2017; Guerra-Junior et al., 2017). Class B medicines require
moderate control by middle level managers, whereas Class C
medicines require only minimum control measures for order and
purchase, and these functions can be delegated to lower level
managers if pertinent since these medicines account for only 5%
of the total budget (Gupta et al., 2007; Mousnad et al., 2016).
However, they represent an appreciable number of stock items
with an appreciable proportion of Vital or Essential medicines
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TABLE 7 | Morbidity pattern at KNH for 2014–2015.
ICD-10 code Disease 2014 2015
n (%) n (%)
S00-T99 Injuries, poisoning and certain other consequences of external
causes, Burns
7274 (15.0) 6958 (14.5)
I00-I99 Diseases of the Circulatory system 5306 (10.9) 5305 (11.0)
A00-B99 Certain infectious and parasitic diseases 4815 (9.9) 5018 (10.4)
C00-D48 Neoplasms 4800 (9.9) 5253 (10.9)
J00-J99 Diseases of the Respiratory system 4774 (9.8) 4818 (10.0)
N00-N99 Diseases of the Genitourinary system 3533 (7.3) 3831 (8.0)
K00-K95 Diseases of the Digestive system 2988 (6.2) 2920 (6.1)
E00-E89 Endocrine, Nutritional and metabolic disorders 2818 (5.8) 2840 (5.9)
G00-G99 Diseases of the Nervous system 1269 (2.6) 1324 (2.8)
M00-M99 Diseases of the Musculoskeletal system and connective tissue 754 (1.6) 844 (1.8)
L00-L99 Diseases of the Skin and subcutaneous tissue 711 (1.5) 690 (1.4)
D50-D59 Diseases of the blood and blood forming organs and certain
disorders involving the immune system
492 (1.0) 503 (1.0)
F00-F99 Mental, Behavioral disorders 368 (0.8) 362 (0.8)
H00-H59 Disease of the Eye and Adnexa 314 (0.6) 354 (0.7)
Total 48484 (100) 48137 (100)
TABLE 8 | Average morbidity patterns and drug expenditure data for the years 2013–2015 at KNH.
ICD-10 code Disease Average N (%) % Average Annual
drug expenditure
S00-T99 Injuries, poisoning and certain other consequences of external
causes, Burns
5698 (14.9) 3.1
I00-I99 Diseases of the Circulatory system 4303 (11.2) 6
C00-D48 Neoplasms 3989 (10.4) 19
A00-B99 Certain infectious and parasitic diseases 3969 (10.4) 26.3
J00-J99 Diseases of the Respiratory system 3741 (9.8) 2.9
N00-N99 Diseases of the Genitourinary system 2900 (7.6) 3.7
K00-K95 Diseases of the Digestive system 2340 (6.1) 1.8
E00-E89 Endocrine, Nutritional and metabolic disorders 2250 (5.9) 11.8
G00-G99 Diseases of the Nervous system 1165 (3.0) 8.5
M00-M99 Diseases of the Musculoskeletal system and connective tissue 654 (1.7) 6.2
L00-L99 Diseases of the Skin and subcutaneous tissue 562 (1.5) 0.3
D50-D59 Diseases of the blood and blood forming organs and certain
disorders involving the immune system
383 (1.0) 9.1
F00-F99 Mental, Behavioral disorders 285 (0.7) 0.6
H00-H59 Disease of the Eye and Adnexa 278 (0.7) 0.6
Total 38292 100
(Table 5); consequently, they should be closely supervised for
Vital and Essential medicines.
A similar study conducted among the Armed Forces Medical
College Hospital in India reported that, out of the 201 different
types of medicines procured, 6.77% (104 medicine types)
consumed 70.03% of the annual drug expenditure comprising
Group A, whilst Group C medicines constituted 73.95% (1136) of
the different types of medicines consumed but only 5% of annual
drug expenditure (Kumar and Chakravarty, 2015). Migbaru et al.
in Ethiopia reported that in 2009, 24 medicine items (9.60%)
consumed 81.2% of the total annual drug expenditure (Group A),
51 items (20.40%) consumed 13.3% of annual drug expenditure
(Group B) and the remaining 175 items (70.00%) consumed
only 5.50% of the total drug budget (Group C). In 2013, 32
items (12.17%) consumed 76.15% of annual pharmaceutical
expenditure (Group A), 47 items (17.9%) consumed 15.6% of
the annual drug budget (Group B), with the remaining 184
items (69.96%) accounting for only 8.26% of the total annual
drug budget (Group C) (Migbaru et al., 2009). Junita and Sari in
Indonesia reported similarly that from 336 different medicines,
26 medicines (7.74%) consumed 70.84% of the annual drug
budget (Class A), 37 medicines (11.01%) consumed 19.23% of
the annual drug budget (Class B), whilst the majority of items
(273 medicine types – 81.25%) accounted for only 9.93% of
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FIGURE 1 | Average annual expenditure for KNH according to the ICD-10 classes for the year 2013–2015.
TABLE 9 | Expenditure on medicines as per the KNH formulary therapeutic categories for 2013–2015.
NO Therapeutic category Total expenditure (Kshs)
2013 2014 2015
(1) Anesthetic and theater agents 31,847,419.50 29,882,455.25 44,372,410.89
(2) Analgesics and Anti-inflammatory drugs 21,328,188.30 25,550,924.38 23,234,426.60
(3) CNS drugs 30,746,197.68 23421524.62 30,264,897.30
(4) Gastrointestinal medicines 4,525,398.72 5,598,815.09 5,183,502.69
(5) Cardiovascular drugs 42,455,458.59 46,506,328.51 47,242,380.52
(6) Anti-infective medicines, Antibacterials 50,513,836.84 68,207,175.34 77,644,113.59
(7) Other Anti-infective medicines 18,321,053.66 23,951,291.04 36,383,120.25
(8) Antineoplastic and immunosuppressive drugs 72,602,978.04 65,927,817.10 72,392,977.51
(9) Antidotes and Endocrine drugs 16,926,707.86 15,209,988.91 19,039,929.92
(10) Topical dermatological preparations 2,994,599.83 1,971,844.96 2,673,963.50
(11) ENT preparations 2,208,031.00 2,456,214.04 2,000,968.50
(12) Respiratory tract drugs 10,476,915.40 6,661,613.78 10,381,563.32
(13) Vitamins and Minerals 6,880,499.45 5,115,727.65 6,054,840.00
(14) Disinfectants and Antiseptics 9,865,037.60 8,891,550.25 9,871,303.56
(15) Plasma substitutes and Parenteral Nutrition 52,725,902.00 55,633,309.13 38,653,487.20
(16) Miscellaneous 14,598,700.00 9,549,277.32 5,873,793.00
(17) Immunologicals 5,265,959.70 6,948,920.00 17,840,256.00
(18) Oxytocics and Antioxytocics 6,342,560.00 4,907,109.50 2,956,310.00
Total 400,625,444.17 406,391,886.87 452,064,244.35
the drug budget (Class C) (Migbaru et al., 2009; Junita and
Sari, 2012). Kastanioti et al in their study in Greece also found
that approximately 9% (30 medicines types) accounting for
nearly 70% of annual pharmaceutical expenditure in 2013 (Class
A), whilst only 11% of items were responsible for nearly 80%
of cumulative pharmaceutical expenditure in 2014 (Kastanioti
et al., 2016). Similalry in the Sudan National Health Insurance
Fund programme, Mousnad et al found that only a small
number of medicine items (n = 80, 16.98%) accounted for
largest proportion of annual expenditure (70.19% – Class A),
whereas a large number of items (n = 288, 61.15% – Class
C) accounted for only 9.92% of total annual drug expenditure
(Mousnad et al., 2016).
The VEN analysis of the KNH drug store revealed that the
majority of medicines belonged to the Vital (V) and Essential
(E) categories, indicating that expenditure in the hospital is
aimed at serving the health care needs of the majority of the
population, which is encouraging. There were a number of
medicines (141) which were non-formulary and were classified
into the V, E, and N categories based on WHO classification
(Kiguba et al., 2017). Migbaru et al. (2009) found that the majority
of medicines in their hospital were also either Vital or Essential,
and they also had the highest expenditure. A study performed
at B. J. Government and Medical College, and Sassoon General
Hospitals, analyzing a smaller number of different medicines,
also showed that Vital medicines represented 148 (50.9%) of
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different medicines procured, Essential medicines 40.2% and
Non-essential medicines at only 8.9% of total medicine items
procured (Poorwa et al., 2013). This contrasts with a study
conducted at the Armed Forces Medical College Hospital in India
reporting that Vital medicines accounting for 13.14%, Essential
drugs (E) for 56.37% and Non-essential medicines for 30.49% of
the 1536 different medicines types in the hospital (ATC Level 5)
(WHO, 2002). Devnani et al. (2010) also had similar findings with
V medicines accounting for 12.11% of procured medicines types,
E at 59.38% and N at 28.51%. Mousnad et al. also found a small
number of items (n = 11, 2.34%) of Class V medicines accounted
for 5.46% of the total drug budget whereas Class N medicines
consisting of 45.01% items accounted for 26.43% of total annual
expenditure (Mousnad et al., 2016).
Medicines belonging to the Vital category require continuous
availability and reasonable safety stock, whilst Essential
medicines require reduced stock levels, and non-essential
medicines minimum managerial control over their availability
and stocks (Devnani et al., 2010). This will be followed up in
our hospital. In addition, non-formulary medicines should
henceforth be considered by the Hospital DTC for possible
inclusion into the Hospital formulary as they consumed only
2.4% of the total hospital expenditure on medicines during the
3 years and were considered necessary, and we will be following
this up.
Our study had comparable results to the study of Kumar and
Chakravarty (2015) which showed that 21, 51.17, and 27.83% of
the medicines belonged to Category I, II, and III, respectively.
Devnani et al. (2010) also reported that 22.09, 54.63, and 23.28%
of the medicines procured were found to belong to category I,
II, and III, respectively, accounting for 74.21, 22.23, and 3.56%,
respectively, of annual drug expenditure. Medicines belonging
to Category I require constant attention to their utilization and
stocks; consequently requiring more selective control through
Hospital DTCs and other measures (Bjorkhem-Bergman et al.,
2013; Lima-Dellamora Eda et al., 2014; Matlala et al., 2017). The
majority of medicines in KNH belong to Category II (47.7% of
total medicine types), are of intermediate value (14% of total
annual expenditure) (Table 6) and are an essential part of patient
care; consequently they also require control and close supervision
by middle level managers in the hospital.
Medicines belonging to the CE category, which are
inexpensive and essential but account for just over 35.4%
of the total medicine types and only on average 2.8% of total
annual drug expenditure (Table 5), should be availed at all times.
Category III (CN) consisting on average 21.3% of medicine types,
but just over 1.1% of the total hospital budget, can be ordered in
bulk to save on ordering costs if there is space available and they
require minimum supervision.
Not surprisingly given the cost of medicines for patients with
cancer and the extent of patients with infection in hospitals in
Kenya (Atieno et al., 2018; Okoth et al., 2018), antineoplastic
medicines and antibiotics consumed the highest amount of
annual drug expenditure (Figure 1 and Table 9). This could be, as
mentioned, that most antineoplastic medicines are expensive and
KNH is currently the only referral hospitals that handles most
of the cancer cases in Kenya (Atieno et al., 2018). Antibiotics
are often highly prescribed, especially in view of high prevalence
of infectious diseases in Kenya including HIV (Okoth et al.,
2018), and since KNH is a referral hospital it stocks most of the
expensive antibiotics including third line carbapenems.
Therapeutic Category and Morbidity
Patterns
The difference between the number of cases and drug expenditure
in ICD-10 classes A00-B99, C00-D48, and D50-D59 (Table 8 and
Figure 1) could be attributed to irrational use of medicines for
the management of these patients. Alternatively, the medicines
used to manage these patients could be expensive as seen
potentially for treatments for patients with cancer (C00-D48) and
infectious diseases (A00-B99); however, potentially necessary to
improve outcomes as well as reduce morbidity and length of stay.
Medicines for neoplasms consumed an average of 19% of the
annual drug budget, and had the majority of the medicines in
Class A. For ICD-10 classes I00-I99 (Diseases of the circulatory
system), J00-J99 (Diseases of the respiratory system), and K00-
K95 (Diseases of the digestive system), there also appears to be
a mismatch between drug expenditure and the number of cases.
This mismatch could be attributed to the use of inexpensive
medicines to manage these cases; alternatively, there is a lack
of enough medicines in the formulary to manage these patients
effectively. Consequently, there is need for further studies on
the reasons for the variability in expenditure and morbidity
following this analysis, and this will be the subject of future
research projects. However, we are mindful that the classification
of diseases may not be that accurate (Holloway and Green, 2003),
although this is not always the case among sub-Saharan countries
(Mashalla et al., 2017).
The majority of medicines used to treat the most common
diseases as per morbidity patterns are in Class A, and include
injectables such as acyclovir, meropenem, heparin, enoxaparin,
and sodium chloride infusion (Table 3). These medicines are
either Vital or Essential and should be available at all times. Most
of the medicines for patients with cancer are expensive but seen
as essential; consequently, care should be taken to provide them.
However, care when considering new treatments for patients with
cancer given the limited health gain with the majority of new
cancer medicines alongside their high prices (Kantarjian et al.,
2013; Cohen, 2017; Godman et al., 2017b) potentially further
increasing unaffordability (Atieno et al., 2018).
Theater medicines also accounted for considerable
expenditure over the 3 years (Table 9); however, data on
the number of cases operated per year is not currently available.
This though will be looked at further in the future to see if any
savings can be made without compromising care. The increase
in expenditure for anti-infective and respiratory tract medicines
over the years (Table 9) could be attributed to an increase in the
number of cases for the two diseases over the years. Again this
will be looked at further in light of our findings.
Injuries including burns are still the third most common cause
of morbidity and mortality in Kenya, and a leading cause of death
in other LMICs (WHO, 2017a). This is consistent with our data
and other reports showing that KNH, being a public referral
hospital, handles the majority of patients with severe injuries
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and burns in Kenya (Botchey et al., 2017; Myers et al.,
2017). These conditions require long term costly treatment;
consequently, most poor patients are referred to KNH where a
single ward can incorporate as many as 100 patients.
Despite being the leading cause of morbidity at KNH, injuries
and burns (5698 cases) accounted for only 3.1% of annual drug
expenditure compared to infectious and parasitic diseases (3969
cases) that had the highest annual drug expenditure at 26.1%. The
mismatch between the number of cases and drug expenditure for
injuries and burns reported in this study may be due to the fact
that expensive surgical dressings and other technologies for these
conditions were excluded from this study because at KNH they
are not purchased directly under the Pharmacy drug budget. This
will be investigated further.
We are aware of a number of limitations with the data
including incomplete and partial data including medicine prices.
There were also incorrect entries and lost data in the health
information systems for the morbidity data and some medicines
are used to treat more than one disease. We also only considered
the acquisition cost of medicines without looking further at their
potential role in for instance reducing hospital length of stay.
In addition, we have only carried out this study at one hospital,
albeit the leading hospital in Kenya typically treating patients
with cancer across Kenya and a referral hospital for patients with
infectious diseases. However, despite this, we believe the findings
give a comprehensive picture of current medicine utilization and
expenditure within KNH providing direction not only to the
senior management in KNH but to other hospitals in Kenya for
the future.
CONCLUSION
ABC analysis showed that whilst Class A medicines represented
an average of only 13.7% of total medicine types procured
they accounted for on average approximately 80% of total drug
expenditure over the 3 years of study. Class C medicines,
whilst being the majority, accounted for only 5% of total drug
expenditure. VEN analysis showed that Vital and Essential
medicines consumed approximately 90–95% of total drug
expenditure over the 3 years with the remaining Non-essential
medicines consuming only 5–11% of total drug expenditure. The
ABC-VEN analysis showed further that items in Category I (AV,
AE, AN, BV, and CV) consumed on average 85% of total annual
drug expenditure, and should be the major focus for assessing
their relative cost-effectiveness with increasing resource pressures
as well as looking to eliminate any out-of-stock situations.
Consequently, we believe the ABC-VEN techniques need to be
adopted routinely by the Hospital Management in this and other
similar hospitals throughout Kenya to ensure the optimal use of
available resources for the patients. This is being followed up to
maximize patient outcomes with available resources.
We are also aware that 20% of the medicines included in this
study were non-formulary. This will again be looked at further
for future inclusion in the hospital formulary such as Human
normal immunoglobulin 5%; alternatively, restrictions placed on
their use.
The TC and morbidity pattern data revealed a mismatch
between drug expenditure and the number of cases seen in the
hospital, which needs further investigation. We believe, based
on our findings, that such analyses should also be routinely
performed to help hospital management teams across Kenya
address gaps between expenditure and the number of cases in
the hospital. As a result, optimize their use of limited resources.
This is now being followed up in our hospital, and we hope
our study stimulates similar research in other hospitals in Kenya
as well as other African countries. DTCs in Kenya and other
sub-Sahara African countries should also focus on expenditures
for antibiotics and antineoplastic medicines as these have been
shown to be a significant proportion of hospital drug expenditure,
which is likely to continue.
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